Clinical Trial Update: Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 trial update reports completion of a study evaluating oral docosahexaenoic acid (DHA) supplementation in cystic fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Docosahexaenoic acid (docosahexaenoic acid)

Snippet

Sponsor: Vanderbilt University | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED